Breaking News

Dr. Blackford Middleton Joins ClosedLoop to Improve Clinical Decisions With AI
ClosedLoop, healthcare’s data science platform, today announced that renowned clinical informatics expert Dr. Blackford Middleton has joined ClosedLoop as Chief Medical Officer. Dr. Middleton and ClosedLoop share a mission to improve every healthcare decision with AI-driven insights, and his decades of experience designing, implementing, and evaluating advanced clinical systems will accelerate ClosedLoop’s progress towards achieving this goal.
At ClosedLoop, Dr. Middleton will help identify relevant informatics standards, support clinical content development and use, and assist in company strategy, product design, and customer success. His perspective and expertise as a national leader on interoperability, healthcare data, provider – and patient-facing systems will help ClosedLoop address some of the industry’s biggest challenges and continue its pursuit of the Quadruple Aim: improving population health, lowering costs, and improving both the patient and provider experience.
“Blackford is deeply passionate about improving healthcare with AI and machine learning at scale, and we are thrilled to have him join the executive team,” said Andrew Eye, CEO and founder. “His understanding of the healthcare delivery system is second to none, and his insight will be invaluable on our journey to help everyone achieve better health outcomes.”
“ClosedLoop is the leader in predictive AI for healthcare—winning the CMS AI Health Outcomes Challenge is testament to that,” said Dr. Middleton. “I’m thrilled to join a leading-edge company that is enabling informaticians and data scientists to transform healthcare delivery. Just having electronic health records (EHRs) in place nationwide is not enough, it is now time to realize their full potential with AI and effectively utilize all available health data to improve care.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more